Epidemiological cut-off value and antibiotic susceptibility test methods for azithromycin in a collection of multi-country invasive non-typhoidal Salmonella.

Agar dilution Antibiotic susceptibility testing Azithromycin Broth microdilution Disk diffusion Epidemiological cut-off Gradient test Non-typhoidal Salmonella Performance

Journal

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
ISSN: 1469-0691
Titre abrégé: Clin Microbiol Infect
Pays: England
ID NLM: 9516420

Informations de publication

Date de publication:
Dec 2022
Historique:
received: 25 01 2022
revised: 03 06 2022
accepted: 09 06 2022
pubmed: 24 6 2022
medline: 25 11 2022
entrez: 23 6 2022
Statut: ppublish

Résumé

Azithromycin is an alternative to treat invasive non-typhoidal Salmonella (iNTS) infections. We determined its epidemiological cut-off (ECOFF) and compared azithromycin susceptibility testing methods for iNTS. We used EUCAST ECOFFinder to determine the minimum inhibitory concentrations (MIC; obtained by broth microdilution) ECOFF and corresponding disk zone diameters of 515 iNTS from blood cultures in Democratic Republic of Congo, Burkina Faso, Rwanda, and Cambodia. Transferable resistance mechanisms were determined by polymerase chain reaction. We compared azithromycin susceptibility testing by semi-automated broth microdilution (customized Sensititre panel; reference), agar dilution, gradient tests (bioMérieux, Liofilchem, HiMedia; read at 80% (MIC80%) and 100% inhibition (MIC100%)), and disk diffusion (Rosco, Oxoid, BD, Liofilchem) for 161 wild- and 198 non-wild-type iNTS. Azithromycin MIC ECOFF was 16 mg/L corresponding to a 12 mm zone diameter; mphA was detected in 192/197 non-wild- and 0/47 wild-type iNTS. Categorical agreement was excellent (≥98%) for all methods. Essential agreement was very good for agar dilution (>90%) but moderate for gradient tests (MIC80%: 52% to 71% and MIC100%: 72% to 91%). Repeatability was good for all methods/brands. Interreader agreement was high for broth microdilution and agar dilution (all ≤1 twofold dilution difference) and disk diffusion (>96% ≤3 mm difference) but lower for gradient tests (MIC80% & MIC100%: 83% to 94% ≤1 twofold dilution difference). Azithromycin ECOFF of iNTS was 16 mg/L, i.e. equal to Salmonella Typhi. Disk diffusion is an accurate, precise, and user-friendly alternative for agar dilution and broth microdilution. Reading gradient tests at 100% instead of 80% inhibition improved accuracy and precision.

Identifiants

pubmed: 35738320
pii: S1198-743X(22)00322-6
doi: 10.1016/j.cmi.2022.06.009
pii:
doi:

Substances chimiques

Azithromycin 83905-01-5
Agar 9002-18-0
Anti-Bacterial Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1615-1623

Informations de copyright

Copyright © 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Auteurs

Bieke Tack (B)

Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium; Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium. Electronic address: btack@itg.be.

Marie-France Phoba (MF)

Department of Microbiology, National Institute for Biomedical Research, Kinshasa, Democratic Republic of the Congo; Department of Microbiology, University Teaching Hospital of Kinshasa, Kinshasa, Democratic Republic of the Congo.

Phe Thong (P)

Sihanouk Hospital Center of Hope, Phnom Penh, Cambodia.

Palpouguini Lompo (P)

IRSS/Clinical Research Unit of Nanoro, Nanoro, Burkina Faso.

Charlien Hupko (C)

Faculty of Medicine, KU Leuven, Leuven, Belgium.

Stefanie Desmet (S)

Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium; Clinical Department of Laboratory Medicine, University Hospitals Leuven, Leuven, Belgium.

Delphine Martiny (D)

Department of Microbiology, Laboratoire des Hôpitaux Universitaires de Bruxelles, Universitaire Laboratorium Brussel (LHUB-ULB), Bruxelles, Belgium; Faculté de Médecine et Pharmacie, Université de Mons (UMONS), Mons, Belgium.

Wesley Mattheus (W)

Division of Human Bacterial Diseases, Sciensano, Uccle, Belgium.

Maria Pardos de la Gandara (M)

Institut Pasteur, Université Paris Cité, Unité des Bactéries Pathogènes Entériques, Centre National de Référence des Escherichia coli, Shigella et Salmonella, Paris, France.

Lisette Mbuyi-Kalonji (L)

Department of Microbiology, National Institute for Biomedical Research, Kinshasa, Democratic Republic of the Congo; Department of Microbiology, University Teaching Hospital of Kinshasa, Kinshasa, Democratic Republic of the Congo.

Laura Kuijpers (L)

Department of Infectious Diseases, Leiden University Medical Center, Leiden, the Netherlands.

Benoit Prevost (B)

Department of Microbiology, Laboratoire des Hôpitaux Universitaires de Bruxelles, Universitaire Laboratorium Brussel (LHUB-ULB), Bruxelles, Belgium.

Barbara Barbé (B)

Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.

Olivier Vandenberg (O)

Center for Environmental Health and Occupational Health, School of Public Health, Université Libre de Bruxelles, Brussels, Belgium; Innovation and Business Development Unit, Laboratoire des Hôpitaux Universitaires de Bruxelles, Universitaire Laboratorium Brussel (LHUB-ULB), Bruxelles, Belgium; Division of Infection and Immunity, Faculty of Medical Sciences, University College London, London, United Kingdom.

Octavie Lunguya (O)

Department of Microbiology, National Institute for Biomedical Research, Kinshasa, Democratic Republic of the Congo; Department of Microbiology, University Teaching Hospital of Kinshasa, Kinshasa, Democratic Republic of the Congo.

Joaquim Ruiz (J)

Grupo de Investigación en Dinámicas y Epidemiología de la Resistencia a Antimicrobianos - "One Health," Universidad Cientifica del Sur, Lima, Peru.

Jan Jacobs (J)

Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium; Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium.

Liselotte Hardy (L)

Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH